Gansu Wuwei Heavy Ion Center - Carbon Ion Cancer Treatment

On June 16, the High-Quality Development of Heavy Ion Therapy and Green Medical Care Model Promotion Conference was held in Guiyang. Gansu Province Wuwei Tumor Hospital showcased the breakthrough efficacy of heavy ion therapy in treating refractory tumors such as liver cancer and pancreatic cancer, leveraging its "dual-center" collaborative advantages. By partnering with insurance and aviation services to create a full-chain guarantee system, the hospital aims to make cutting-edge technology accessible to patients worldwide.

On June 14, the High-Quality Development Promotion Conference for Heavy Ion Therapy was held in Kunming. Leveraging the "Bragg Peak" effect, dual centers in Wuwei and Lanzhou have used precision technology to tackle difficult-to-treat cancers such as liver and pancreatic cancer. By innovating a model integrating medical care, insurance, and air transport, they are lighting up new hope for patients' lives.

On June 6, 2026, the "2026 Precision Radiotherapy · Leading the Frontier" conference was held at the Wuwei Heavy Ion Center. Focusing on cutting-edge technologies such as heavy ion therapy and CyberKnife, the event discussed clinical treatment strategies for tumors including lung cancer, while showcasing breakthroughs in domestic heavy ion technology and achievements in an integrated, full-chain diagnostic and therapeutic system.

Adenoid cystic carcinoma of the trachea is difficult to cure? The Wuwei Heavy Ion Center has introduced domestic heavy (carbon) ion technology to precisely target tumors while sparing surrounding healthy tissue. This offers a non-invasive and highly effective new solution for patients with surgical limitations, those unresponsive to conventional radiotherapy, and elderly individuals. With over 2,800 cases treated so far, this approach has significantly improved quality of life and opened a new chapter in airway tumor treatment.

The Wuwei Heavy Ion Center offers precise carbon ion therapy for malignant eye tumors, providing globe-salvaging and vision-preserving treatment options for conditions such as melanoma and adenoid cystic carcinoma. With a short treatment course and costs of approximately 130,000 RMB, this approach achieves non-invasive cure, avoiding enucleation while preserving ocular appearance and quality of life.

Based on real-world data from 24 laryngeal cancer patients treated at the Gansu Wuhui Heavy Ion Center, this study summarizes the efficacy of heavy (carbon) ion therapy in early-stage, advanced-stage, and recurrent laryngeal cancer. The data indicate that survival rates are comparable to international standards and significantly superior to traditional therapies. This approach is particularly suitable for patients requiring voice preservation or those ineligible for surgery, offering a new choice for precise, low-toxicity curative treatment.

Prostatic sarcoma is an extremely rare but highly malignant tumor of the prostate that originates from mesenchymal tissues (such as muscle and vascular connective tissue), distinguishing it fundamentally from common prostate cancer, which arises from glandular epithelial cells.

From Marie Curie's discovery of radium, which opened the century-long exploration of nuclear medicine, to today's precise radiopharmaceuticals becoming a core weapon in combating advanced tumors, nuclear medical technology has continuously evolved, lighting up hope for survival for patients with difficult-to-treat cancers. Recently, the Department of Nuclear Medicine at Wuwei Tumor Hospital in Gansu Province is about to complete all necessary approval procedures, becoming the first medical institution in Gansu Province and a leading facility in Northwest China with clinical application qualifications for radium-223 (²²³Ra). This enables routine α-particle targeted radionuclide therapy for bone metastases in castration-resistant prostate cancer, filling a technological gap in the Northwest region and marking a new milestone in the comprehensive precision diagnosis and treatment capabilities of our hospital's nuclear medicine department.